STAT+: ImmunityBio’s soon-Shiong mischaracterized talks w...

What’s Happening

Okay so ImmunityBio Chairman Patrick soon-Shiong mischaracterized talks with the FDA over the company’s cancer drug, sources say.

Adams Biotech Scorecard Adams Biotech Scorecard STAT Plus: As FDA raises bar in rare diseases, pivotal moment nears for RegenxBio By Adam Feuerstein Adams Biotech Scorecard Adams Biotech Scorecard STAT Plus: JPM Week 2026 is over. (we’re not making this up)

Here’s why By Adam Feuerstein Adams Take Adams Take STAT Plus: Why the JP Morgan conference is important — but not make-or-break By Adam Feuerstein Adams Biotech Scorecard Adams Biotech Scorecard STAT Plus: Ocular Therapeutix faces looming test of a more durable eye treatment By Adam Feuerstein Adams Biotech Scorecard Adams Biotech Scorecard STAT Plus: Biotech, growing up, is turning profitable By Adam Feuerstein STAT Plus: AI biotech founded by ex-Google CEO Eric Schmidt is raising $150 million By Brittany Trang STAT Plus: Alabama hospital system would gain monopoly with proposed $450 million deal By Bob Herman STAT Plus: Dozens of hospitals demand better security for patient record sharing in letter to officials By Brittany Trang STAT Plus: At JPM 2026, Mehmet Oz and top Trump health officials explain their thinking to hospital leaders By Tara Bannow STAT Plus: Endometriosis often takes years to diagnose.

Why This Matters

This is the kind of health news that affects everyday decisions.

Medical professionals are taking note of this development.

The Bottom Line

This story is still developing, and we’ll keep you updated as more info drops.

What’s your take on this whole situation?